Physician profile
Mitchell B Strominger
NPI 1528026184
$64,017.02
in general payments reported to CMS, 2019-2025
13 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $246 · 2021: $397 · 2022: $7,454 · 2023: $19K · 2024: $25K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Honoraria: $17K · Consulting Fee: $9,450 · Food and Beverage: $4,739 · Travel and Lodging: $3,453 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,525.00 |
| Honoraria | $16,743.75 |
| Consulting Fee | $9,450.00 |
| Food and Beverage | $4,738.51 |
| Travel and Lodging | $3,452.83 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35,896.82 | 2024-2025 | Tepezza, Uplizna |
| Horizon Therapeutics Plc | $27,130.35 | 2020-2023 | Tepezza |
| Ucb, INC. | $223.36 | 2023-2025 | Rystiggo, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $181.17 | 2022-2024 | Ultomiris, Koselugo |
| Alcon Vision LLC | $142.45 | 2024 | Clareon |
| Pfizer INC. | $132.17 | 2025 | |
| Genentech, INC. | $105.16 | 2020 | |
| Dompe US, INC. | $65.73 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $41.61 | 2020 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Argenx US, INC. | $24.91 | 2025 | Vyvgart Hytrulo |
| Mallinckrodt Hospital Products INC. | $20.65 | 2022 | |
| Travere Therapeutics, INC. | $13.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Strominger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.